medigraphic.com
ISSN 1025-0255 (Electronic)

2017, Number 4

<< Back Next >>

AMC 2017; 21 (4)

Results of liver biopsy in the diagnosis of non-alcoholic fatty liver

Creagh GJ, Suárez SB, Hernández RM, Martínez PT

Language: Spanish
References: 27
Page: 518-527
PDF size: 493.34 Kb.


ABSTRACT

Background: nonalcoholic liver disease is an entity that has a broad clinical-pathological spectrum including simple steatosis and non-alcoholic steatohepatitis. This is increasingly recognized as an important cause of morbidity and mortality. Objective: to describe the results of liver biopsy in the diagnosis of non-alcoholic fatty liver. Methods: a descriptive cross-sectional study was carried out from September 2014 to June 2016 at Manuel Ascunce Domenech Hospital. SPSS program was used to process statistical data. The results were presented in tables and relative and absolute frequencies were used. Results: most patients were 60 of age and over. The number of patients increased progressively in relation to age. As for sex, there were differences between the two, with women predominating over men. Almost all patients were asymptomatic, and those with symptoms, pain in the right hypochondrium and hepatomegaly were the most frequent. In the majority of patients, grade II non-alcoholic fatty liver followed by grade I was found. Only 35 patients presented grade III. Conclusions: the most frequent associated diseases were diabetes mellitus, obesity and overweight. Non-alcoholic fatty liver Grade II was the most frequent and the diagnosis of hepatic steatosis was made in almost all the patients.


REFERENCES

  1. Bernsmeier C, Dill MT, Provenzano A, Makowska Z, Krol I, Muscogiuri G, et al. Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation. Lab Invest [Internet]. 2016 Jul 18 [citado 2016 Aug 10];96(9):[about 9 p.]. Available from: http://www.nature.com/labinvest/journal/v96/n9/full/labinvest201675a.html

  2. Mottillo EP, Desjardins EM, Crane JD, Smith BK, Green AE, Ducommun S, et al. Lack of Adipocyte AMPK Exacerbates Insulin Resistance and Hepatic Steatosis through Brown and Beige Adipose Tissue Function. Cell Metab [Internet]. 2016 Jul 12 [citado 2016 Aug 10];24(1):[about 12 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239668/.

  3. Koroglu E, Canbakan B, Atay K, Hatemi I, Tuncer M, Dobrucali A, et al. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease. Turk J Gastroenterol [Internet]. 2016 Jul [citado 2016 Aug 10];27(4):[about 6 p.]. Available from: www.turkjgastroenterol.org/sayilar/293/buyuk/361-6y.pdf

  4. Yun S, Choi D, Lee KG, Kim HJ, Kang BK, Kim H, et al. Cholecystectomy Causes Ultrasound Evidence of Increased Hepatic Steatosis. World J Surg [Internet]. 2016 Jun [citado 2016 Aug 10];40(6):[about 10 p.]. Available from: http://link.springer.com/article/10.1007%2Fs00268-015-3396-7

  5. Huang Q, Yu J, Zhang X, Liu S, Ge Y. Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease. Biomed Rep [Internet]. 2016 Aug [citado 2016 Aug 10];5(2):[about 5 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27446539/.

  6. Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte F, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol [Internet]. 2016 Mar 18 [citado 2016 Aug 10];3(1):[about 8 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27110380/.

  7. Ma DW, Arendt BM, Hillyer LM, Fung SK, McGilvray I, Guindi M, et al. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects. Nutr Diabetes [Internet]. 2016 Jul 18 [citado 2016 Aug 10];6(7):[about 9 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27428872/.

  8. Andrade GC, Fujise LH, Santana JEF, Oliveira F, Silva RC. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study - sample of Sao Jose do Rio Preto. Rev Assoc Med Bras [Internet]. 2016 May-Jun [citado 2016 Aug 10];62(3):[about 8 p.]. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302016000300218&lng=en&nrm=iso&tlng=en

  9. Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, et al. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol [Internet]. 2016 Aug [citado 2016 Aug 10];51(8):[about 1 p.]. Available from: www.tandfonline.com/doi/full/10.3109/00365521.2016.1161066

  10. Demir S, Unubol M, Aypak SU, Ipek E, Aktas S, Ekren GS, et al. Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats. Int J Endocrinol [Internet]. 2016 Apr 7 [citado 2016 Aug 10];2016:[about 9 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838785/.

  11. Lombardi R, Pisano G, Fargion S. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. Int J Mol Sci [Internet]. 2016 Apr [citado 2016 Aug 10];17(4):[about 15 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849004/.

  12. Sanchez-Pareja A, Clement S, Peyrou M, Spahr L, Negro F, Rubbia-Brandt L, et al. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World J Gastroenterol [Internet]. 2016 Abr 14 [citado 2016 Aug 10];22(14):[about 11 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814736/.

  13. Alcázar Casielles M del. Hígado graso no alcohólico en pediatría. Rev Cubana Med Gen Integr [Internet]. Dic 2013 [citado 23 May 2017];29(4):[aprox. 19 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252013000400009&lng=es

  14. Piñeiro Lamas R, Fernández-Brito Rodríguez JE. Hígado graso no alcohólico como señal de aterosclerosis. Rev Cubana Invest Bioméd [Internet]. Mar 2013 [citado 23 May 2017];32(1):[aprox. 8 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002013000100001&lng=es

  15. Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol [Internet]. 2016 Jul 21 [citado 2016 Aug 10];22(27):[about 10 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945989/.

  16. Pérez Lorenzo M, Franco Estrada S, Winograd Lay R, Angulo Pérez O. Aspectos clínico-patológicos del hígado graso no alcohólico. Rev Cub Med Mil [Internet]. Oct-Dic 2003 [citado 10 Ago 2016];32(4):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572003000400005&nrm=iso

  17. Vanegas R CM, Restrepo RC, Vargas GN, Marín C AE, Martínez S LM, Yepes D CE, et al. Caracterización de pacientes con enfermedad del hígado graso no alcohólica en un hospital de alta complejidad, Colombia 2013. Rev Col Gastroenterol [Internet]. Oct-Dic 2014 [citado 10 Ago 2016];29(4):[aprox. 5 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572014000400002&nrm=iso

  18. Herrera González A, Nasiff Hadad A, Arus Soler E, Cand Huerta C, León N. Hígado graso: Enfoque diagnóstico y terapéutico. Rev cubana med [Internet]. Ene-Mar 2007 [citado 10 Ago 2016];46(1):[aprox. 6 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232007000100009&nrm=iso

  19. Goffredo M, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology [Internet]. 2016 Jan [citado 2016 Aug 10];63(1):[about 9 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688225/.

  20. Pérez Lorenzo M, Duarte Castillo N, Montero González T, Franco Estrada S, Winograd Lay R, Brizuela Quintanilla RA. Prevalencia del hígado graso no alcohólico en muestras de biopsias hepáticas. Rev Cub Med Mil [Internet]. Oct-Dic 2006 [citado 10 Ago 2016];35(4):[aprox. 6 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572006000400006&nrm=iso

  21. Díaz Fondén J, Pereira Despaigne OL, León Columbié A, Del Valle Díaz S, Hodelín Tablada R. Relación entre los hallazgos ecográficos, laparoscópicos e histológicos en pacientes con esteatosis hepática no alcohólica. MEDISAN [Internet]. Mar 2015 [citado 11 Abr 2017];19(3):[aprox. 9 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015000300008&lng=es

  22. Cotrim HP, Oliveira CP, Coelho HS, Alvares-da-Silva MR, Nabuco L, Parise ER, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey. Clinics (Sao Paulo) [Internet]. 2016 May [citado 2016 Ago 10];71(5):[about 4 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874267/.

  23. Piñeiro Lamas R, Fernández-Brito Rodriguez JE. Hígado graso no alcohólico como señal de aterosclerosis. Rev Cubana Invest Bioméd [Internet]. Ene-Mar 2013 [citado 10 Ago 2016];32(1):[aprox. 5 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002013000100001&nrm=iso

  24. Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol [Internet]. 2016 [citado 2016 Aug 10];51(4):[about 9 p.]. Available from: http://www.tandfonline.com/doi/full/10.3109/00365521.2015.1107620

  25. Hamlin AN, Basford JE, Jaeschke A, Hui DY. LRP1 Protein Deficiency Exacerbates Palmitate-induced Steatosis and Toxicity in Hepatocytes. J Biol Chem [Internet]. 2016 Aug 5 [citado 2016 Aug 10];291(32):[about 10 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27317662

  26. Van Meer S, van Erpecum KJ, Sprengers D, Klumpen HJ, Jansen PL, Ijzermans JN, et al. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol [Internet]. 2016 Aug [citado 2016 Aug 10];28(8):[about 7 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27196679.

  27. Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, et al. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver. J Immunol [Internet]. 2016 Jan 1 [citado 2016 Aug 10];196(1):[about 9 p.]. Available from: http://www.jimmunol.org/content/196/1/97.long




2020     |     www.medigraphic.com